31 January, 2011 - Verva Pharmaceuticals Ltd. is pleased to report that Isis Pharmaceuticals Inc. (Nasdaq: ISIS) has formally added ISIS-FGFR4Rx (fibroblast growth factor receptor 4 antisense oligonucleotide) to its development pipeline. In August 2009, Verva announced an agreement providing Isis an exclusive license to Verva’s intellectual property targeting FGFRs with antisense technology for the treatment of metabolic disorders, including obesity. ISIS-FGFR4Rx is the first drug in Isis’ metabolic franchise to treat obesity.Further details on the ISIS-FGF4Rx program can be found in the recent Isis press release at www.isispharm.com.
Verva CEO Vince Wacher commented: “Isis has been an excellent partner and we are very pleased with the results from our collaborative work on this important target. Isis has advanced its FGFR anti-obesity drug into development... Verva Pharmaceuticals' Press Release -
